ID
45804
Beskrivning
Principal Investigator: Jean J. Zhao, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA MeSH: Breast Neoplasms,Neoplasm Metastasis,Brain Neoplasms,Neoplasm Transplantation,Molecular Targeted Therapy https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001063 We have developed orthotopic patient-derived xenograft models of HER2 positive breast cancer metastasized into the brain of patients to test novel therapeutic strategies. In this study, we identified a novel combinatorial therapeutic strategy that has resulted in a durable remission and markedly increased overall survival in majority of patient-derived xenograft (PDX) models tested. We performed whole exome sequencing analysis of these PDX tumors and their matched blood and patient samples to investigate drug sensitive and resistance mechanisms. Our sequencing data revealed an interesting association of genotyping and phenotyping with tumors responses to drug treatment.
Länk
Nyckelord
Versioner (1)
- 23/6/23 23/6/23 - Chiara Middel
Rättsinnehavare
Jean J. Zhao, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Uppladdad den
23 de junio de 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs001063 Genomic Characterization of PDX Models for Breast Cancer Brain Metastases
This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs and consent information.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This subject phenotype table contains subject ID, gender, and age at surgery.
- This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
Similar models
This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs and consent information.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This subject phenotype table contains subject ID, gender, and age at surgery.
- This sample attributes table contains sample ID, analyte type, whether the sample is tumor or from PDX, histological type, brain metastases HER2 status, brain metastases ER status, brain metastases PR status, and patient information before surgery on target therapy, chemotherapy, hormone therapy and radiation.
C1299222 (UMLS CUI [1,2])
C0456205 (UMLS CUI [1,2])
C0936012 (UMLS CUI [1,3])
C4050317 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
C1512413 (UMLS CUI [1,2])
C0034804 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,3])
C2919590 (UMLS CUI [1,2])
C2985566 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])
C0392920 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])
C0279025 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])
C1522449 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0543467 (UMLS CUI [1,4])